FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Richard Dillon, Anjum Khan et al.|Leukemia|2023Cited by 48
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trialsNicola Potter, Richard Dillon, Jelena Jovanović et al.|The Lancet Haematology|2025Cited by 9